UPDATE: Applied Genetic Technologies Corp. (AGTC) PT Raised to 'Street High' $35 at Roth Capital

February 1, 2021 9:34 AM EST
Get Alerts AGTC Hot Sheet
Price: $3.73 +3.04%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 23 | New: 31
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - February 1, 2021 9:36 AM EST)

Roth Capital analyst Zegbeh Jallah raised the price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to a 'Street High' $35.00 (from $30.00) while maintaining a Buy rating.

The analyst comments "Wednesday, after-market-close, AGTC press-released encouraging data from its Phase 1/2 studies of AGTC-402 in Achromatopsia (ACHM) patients that typically have little-to-no photoreceptor function, and experience extreme light discomfort. The update from these patients with CNGB3 and CNGA3 mutations was indeed the very first quantitative evidence of visual sensitivity improvements. More updates are expected in 2021, but we view this is as a strong indication of AGTC-402's efficacy potential, and more broadly AGTC's gene therapy platform, supporting our price target increase."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Roth Capital